Epimède

Epimède SA is a venture capital firm located in Liège, Belgium, established in 2015. The firm specializes in providing early-stage and growth capital investments to small and medium-sized enterprises, particularly those in the technology sector. Its investment focus includes life sciences, such as biology and biotechnology, as well as engineering services, medtech, cleantech, and corporate services. Epimède typically invests between €1 million and €7 million in companies that have fewer than 500 employees, net capital assets not exceeding €75 million, and are not predominantly owned by non-SMEs. The firm aims to support companies with growth potential and takes an active role in their governance by participating in the Board of Directors and influencing key strategic decisions. With a strategic exit plan spanning three to five years, Epimède is dedicated to fostering the development of innovative businesses primarily based in Wallonia.

Marc Foidart

Co-Founder and Investment Manager

5 past transactions

ImCyse

Series B in 2021
ImCyse SA is a clinical-stage biopharmaceutical company based in Liège, Belgium, that specializes in developing active immunotherapies aimed at treating and preventing severe chronic autoimmune diseases linked to immune system disruptions. Founded in 2010, ImCyse utilizes a unique technology platform that focuses on the administration of Imotopes™, specifically modified peptides that generate cytolytic CD4 T-cells. These T-cells selectively eliminate antigen-presenting cells and autoantigen-specific lymphocytes, targeting the underlying causes of diseases like type 1 diabetes and multiple sclerosis. ImCyse's innovative approach not only aims to provide therapeutic alternatives where none exist but also seeks to cure patients without compromising their immune defenses. The company has demonstrated proof of concept across several indications and has successfully completed its first clinical trial for type 1 diabetes, yielding promising results while developing additional Imotopes™ for various autoimmune conditions.

Endo Tools Therapeutics

Series D in 2021
Endo Tools Therapeutics S.A. is a medical device company based in Gosselies, Belgium, founded in 2008. The company specializes in the development and manufacture of innovative therapeutic devices for gastroenterologists, focusing on flexible endoscopic interventions. Endo Tools Therapeutics is currently working on a catheter that will enhance therapeutic capabilities in interventional gastroenterology by adding therapeutic channels and degrees of freedom. The company's products aim to address conditions such as obesity, digestive tract tumors, and diabetes, enabling efficient surgical endoscopy through advanced techniques like flexible endoscopic suturing and tissue apposition. Additionally, the company has developed the ENDOMINA platform, which provides gastroenterologists with an open system for performing therapeutic procedures.

Endo Tools Therapeutics

Series C in 2019
Endo Tools Therapeutics S.A. is a medical device company based in Gosselies, Belgium, founded in 2008. The company specializes in the development and manufacture of innovative therapeutic devices for gastroenterologists, focusing on flexible endoscopic interventions. Endo Tools Therapeutics is currently working on a catheter that will enhance therapeutic capabilities in interventional gastroenterology by adding therapeutic channels and degrees of freedom. The company's products aim to address conditions such as obesity, digestive tract tumors, and diabetes, enabling efficient surgical endoscopy through advanced techniques like flexible endoscopic suturing and tissue apposition. Additionally, the company has developed the ENDOMINA platform, which provides gastroenterologists with an open system for performing therapeutic procedures.

Ncardia

Series B in 2017
Ncardia is a biotechnology company focused on expediting the drug discovery and development process. The company leverages human induced pluripotent stem cell (hiPSC) technology to create predictive human cellular assay systems, which are used for safety and efficacy testing of drug candidates. Additionally, Ncardia enhances cardiovascular and neural drug screening, providing researchers and drug discovery companies with tools to better understand human disease biology. This approach aims to accelerate the overall drug discovery process, facilitating the development of safer and more effective therapeutic options.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.